Form 4: Tarsus Pharmaceuticals Executive Dianne C. Whitfield Sells Shares to Cover Tax Obligations

Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, sold shares of common stock between March 18 and March 20, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• Dianne C. Whitfield, the Chief Human Resources Officer of Tarsus Pharmaceuticals, sold shares of the company's common stock.
• The sales occurred over three days: March 18, 2025, March 19, 2025, and March 20, 2025.
• A total of 2,315 shares were sold on March 18 at a price of $46.29 per share.
• On March 19, 2,259 shares were sold at $47.4 per share.
• Finally, on March 20, 2,137 shares were sold at $50.11 per share.
• These sales were executed to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• The sales were mandated by Tarsus Pharmaceuticals' policy of using a 'sell to cover' transaction to satisfy these tax obligations, and do not represent discretionary transactions by Whitfield.
• Following these transactions, Whitfield directly owns 46,355 shares of Tarsus Pharmaceuticals' common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale of shares to cover tax obligations, not indicative of a change in the executive's confidence in the company.

Industry Context

Executive share sales are a common occurrence, particularly to cover tax obligations related to equity compensation. The 'sell to cover' mechanism is a standard practice.

Stakeholder Impact

• The share sales may have a minor dilutive effect on existing shareholders, but the impact is likely minimal given the relatively small number of shares involved.

Key Dates

Keywords

Tarsus Pharmaceuticals, Dianne C. Whitfield, Form 4, Share Sale, Restricted Stock Units, Tax Withholding, Executive Compensation, Insider Trading